Cardio-oncology & otherCohort study
Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance
- Retrospective cohort study
- single-centre (tertiary cancer center)
Authors' conclusion
Less frequent LVEF monitoring in low-risk patients may optimize resource use and reduce patient burden without compromising safety.
Study context
- Population
- Patients with HER2-positive breast cancer treated with trastuzumab at a tertiary cancer center29.8% also received anthracyclines
- Participants
- 496 patients
- Exposure
- Cancer therapy-related cardiac dysfunction (CTRCD) incidence by HFA/ICOS baseline risk category
- Outcome
- Incidence of trastuzumab-associated CTRCD
- Follow-up
- Median 51 months
Main finding
As reported in the abstract
CTRCD
- Overall CTRCD incidence
- 8.7%
Observational data: associations, not effects.
Further findings
| Outcome | Low risk | Medium risk | High or very high risk |
|---|---|---|---|
| HF incidence · median follow-up 51 months | 0.4% | 2.1% | Not reported in the abstract |
- Heart failure (HF) incidence — Overall HF with CTRCD
- 1.6%
- HF incidence — HF in high-risk patients
- 11%
HF incidence · median follow-up 51 months
- No HF in low- or medium-risk patients receiving trastuzumab without anthracyclines
Original publication
Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance. JACC CardioOncol. Published 25 February 2025. doi:10.1016/j.jaccao.2024.12.007
Summarised from the published abstract; every number is checked against it